- FDA U-turn triggers crash: uniQure (NASDAQ: QURE) shares fell over 50% in one day after U.S. regulators said current clinical data for its experimental Huntington’s disease gene therapy is not adequate for approvalreuters.com. This reversal comes just weeks after uniQure’s trial results were hailed as “game-changing”fiercebiotech.com.
- Wild price swing: QURE stock plummeted from about $68 to the low-$30s, erasing roughly half of its market value (now ~$2.1 B)stockanalysis.com. It hit an intraday low near $23 before partially rebounding to ~$34stockinvest.us, still down ~54% on the newsbenzinga.com.
- Surprise FDA setback: The FDA no longer agrees that uniQure’s Phase 1/2 data (with external control) can support a BLA (marketing application) under accelerated approvalreuters.com – a “drastic change” from prior guidance, uniQure’s CEO saidglobenewswire.com. The timeline for approval is now unclear, likely delaying any U.S. launch beyond 2026reuters.com.
- Analyst reactions: Experts call this a major regulatory setbackreuters.com. Guggenheim’s analyst noted the FDA now sees uniQure’s analysis as “post hoc” (not pre-specified)reuters.com, and another analyst warned new trials or data may be neededreuters.com. Some have cut price targets (e.g. one lowered from $76 to $53benzinga.com), though the pre-news consensus target was ~$68 with a Strong Buy ratingstockanalysis.com.
- Investor sentiment & fallout: The shock has rattled biotech investors – uniQure’s stock had soared ~300% in September after positive trial datafiercebiotech.com, and now enthusiasm has flipped to disappointment. Shareholder rights law firms quickly launched investigations for potential securities fraud (citing the 57% one-day plunge)businesswire.combusinesswire.com, reflecting investor outrage.
- Technical picture: Technically, QURE is in free-fall territory. The gap-down left no clear support levels; shares traded in a wide ~$22–$36 range on the crash daystockinvest.us. Volume spiked to ~30 million shares (vs. ~1–2 million typical), indicating intense selling pressurestockinvest.us. The stock is now well below key moving averages (which sit around $52–$62)stockinvest.us, suggesting overhead resistance
UniQure Stock Plunges 50% on FDA Shocker – What’s Next for QURE’s Gene Therapy Ambitions?
Latest article
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
